05.04.2013 Views

U.S.-Korea Free Trade Agreement: Potential Economy-wide ... - USITC

U.S.-Korea Free Trade Agreement: Potential Economy-wide ... - USITC

U.S.-Korea Free Trade Agreement: Potential Economy-wide ... - USITC

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

The section on measures related to regulated products contains provisions that govern the<br />

regulatory approval and marketing of pharmaceutical or agricultural chemical products. The<br />

data exclusivity provisions would preclude reliance by another person, without consent of<br />

the submitter, on safety or efficacy information provided in support of a new pharmaceutical<br />

product, or evidence of the marketing approval of that product, for a period of at least 5 years<br />

from the date of marketing approval. The data exclusivity period for an agricultural chemical<br />

product would be at least 10 years from marketing approval. In cases where new clinical<br />

information, or evidence of marketing approval based on new information, is submitted in<br />

support of a pharmaceutical product containing a previously approved chemical entity, the<br />

data exclusivity period would be at least 3 years. 98 The section contains a new provision,<br />

which clarifies that a party may take measures to protect public health in accordance with<br />

the Declaration on the <strong>Trade</strong>-Related Aspects of Intellectual Property Rights (TRIPS)<br />

<strong>Agreement</strong> and Public Health (the Doha Declaration), notwithstanding these data exclusivity<br />

provisions. Later in the IPR chapter, the parties affirm their commitment to the Doha<br />

Declaration and confirm that the obligations of the IPR chapter would not prevent a party<br />

from taking measures to protect public health by promoting access to medicine for all. 99<br />

The section on measures related to regulated products also would require the implementation<br />

of measures in the marketing approval process to prevent the approval of generic drugs<br />

during the term of the patent without the patent owner’s consent (a “patent linkage”<br />

provision), including a requirement that the patent owner be notified of the identity of a<br />

person seeking marketing approval during the patent term. 100<br />

Enforcement<br />

The enforcement section of the FTA contains detailed measures intended to promote full and<br />

effective IPR enforcement. It contains general obligations, civil and administrative procedure<br />

and remedies provisions, provisional measures, special requirements related to border<br />

measures, criminal procedures and remedies, and provisions on liability of Internet service<br />

providers. In particular, <strong>Korea</strong> agrees to supplement its civil remedies with a regime of<br />

statutory damages, costs, and attorney’s fees and to provide criminal remedies for trafficking<br />

in counterfeit labels and the illegal recording of audiovisual works (so-called<br />

“camcording”). 101<br />

Side Letters<br />

The IPR chapter includes a series of side letters addressing Internet service provider<br />

obligations, copyright infringement on university campuses, enforcement against online<br />

piracy, and patent linkage. More specifically, the first side letter contains detailed provisions<br />

for an effective “notice and takedown” process for Internet service providers when online<br />

materials are claimed to be infringing and when it is asserted that online materials should not<br />

have been removed from the Internet. The second side letter would require the <strong>Korea</strong>n<br />

98 Ibid., Article 18.9.1-2.<br />

99 Ibid., Articles 18.9.3 and 18.11. These new provisions are the result of a “Bipartisan <strong>Trade</strong> Deal”<br />

between the Office of the U.S. <strong>Trade</strong> Representative and certain Members of Congress. USTR, “Bipartisan<br />

<strong>Trade</strong> Deal,” May 2007, 3.<br />

100 Ibid., Article 18.9.5.<br />

101 Ibid., Articles 18.10.6, 18.10.28, and 18.10.29.<br />

D-27

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!